Trader consensus favoring no new COVID variant of concern before 2027 stems primarily from the stable global circulation of JN.1-descendant lineages such as XFG and NB.1.8.1, which dominate sequencing data without triggering escalation to variant-of-concern status. Recent FDA approvals of 2026-2027 vaccines targeting XFG, alongside similar authorizations in Canada, reflect matched antigenic updates that align with prevailing strains and reduce the likelihood of rapid immune escape. WHO monitoring shows BA.3.2 increasing in some regions yet exhibiting lower fitness and no substantial rise in disease burden or transmissibility, while overall test positivity and severe outcomes remain low compared with prior years. With only months remaining until 2027 and no novel lineage demonstrating the growth advantage or public-health impact seen in past VOCs, these developments reinforce the 77.5% implied probability for no new designation.